Pratiksha Chem. (531257)
TurnaroundScore breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹23.5 |
| Market Cap | ₹13.61 Cr |
| P/E Ratio | 0 |
| ROCE | -150.99% |
| ROE | 75.84% |
| Dividend Yield | 0% |
| Profit Growth | 140.48% |
| Debt/Equity | — |
| Sales Growth | -90.48% |
| 52-Week Range | ₹15.01 — ₹27.75 |
| Sector | Chemicals & Petrochemicals |
| Book Value | ₹7.1 |
Strengths
- Book value of ₹7.10 per share provides some tangible asset backing
- Piotroski F-Score of 5 suggests moderate financial health despite operational stress
- Market cap of ₹14 Cr is tiny, leaving room for potential strategic interest or special situations
- Stock is trading within its 52-week range, not in freefall
Concerns
- Latest quarter shows zero sales and zero net profit – business appears non-operational
- ROCE at -150.99% indicates severe operational losses relative to capital employed
- Sales declined by 90.48%, reflecting either a collapse in demand or cessation of core activities
- Trading at a P/B of 3.31, a steep premium to book value, while earning nothing
AI Analysis
I read the figures for Pratiksha Chem with growing unease. A specialty chemical company that reported no sales and no profit in its latest quarter, a 90% collapse in sales, and a negative return on capital of 151% – this is not a business; it is an empty shell. The market prices it at ₹23.50, more than three times book value of ₹7.10, for a company that cannot earn its keep. The 75.84% ROE is an arithmetic illusion, caused by a tiny equity base, not genuine profitability. As Graham would say, price is what you pay, value is what you get. Here we get no earnings, no dividends, no explanation of promoter holding, and no sales. The 140% profit growth is meaningless when the starting point is zero. Even the Piotroski F-score of 5 provides little comfort; it suggests some balance-sheet stability, but in a business with no operations, that is like praising the foundation of a house without walls. The ₹14 crore market cap may sound small, but for a stock trading at a premium to book with zero revenue, the margin of safety is absent. Buffett would say it is far better to buy a wonderful company at a fair price than a fair company at a wonderful price. This is neither wonderful nor fair. I would keep this on my watchlist only to see if management brings in real business, new assets, or a clear turnaround plan. Until sales recover and ROCE turns positive, I will not put a rupee into Pratiksha Chem.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer